No Data
Morgan Stanley: Raises the Target Price for WEIGAO GROUP (01066) to HKD 5.90 and maintains a "Shareholding" rating.
Morgan Stanley predicts that overall sales will grow by 9% and 7% in 2025 and 2026 respectively, with profit growth slowing down, as Morgan Stanley remains cautiously optimistic about the contribution of new products and regulatory impacts.
Everbright: Import substitution is expected to accelerate, pay attention to the rising market share of domestic surgical robots.
Everbright stated that the import substitution is expected to accelerate, paying attention to the rise in market share of domestic surgical robots.
China Securities Co.,Ltd.: It is recommended to focus on the new growth and integration opportunities in the Industry.
China Securities Co.,Ltd. remains bullish on high-quality Innovative Drugs companies in 2025 and actively focuses on cutting-edge technologies in pharmaceuticals and medical devices.
WEIGAO GROUP (01066.HK) repurchased 0.828 million shares for 4.37 million Hong Kong dollars on April 8.
Gelonghui April 8丨WEIGAO GROUP (01066.HK) announced that on April 8, 2025, it spent HKD 4.37 million to repurchase 0.828 million shares, with a repurchase price of HKD 5.16-5.36 per share.
Shandong Weigao Group Medical Polymer (HKG:1066) Seems To Use Debt Rather Sparingly
WEIGAO GROUP (01066.HK) spent 2.8361 million HKD to buy back 0.4688 million shares on April 3.
On April 3, Gelonghui announced that WEIGAO GROUP (01066.HK) repurchased 0.4688 million shares at a cost of 2.8361 million Hong Kong dollars, with a buyback price of 5.99-6.1 Hong Kong dollars per share on April 3, 2025.
Cui Nyonya Kueh : Tomorrow got class??